BASKING RIDGE, N.J., Dec. 1 Regado Biosciences, Inc.,announced today David J. Mazzo, Ph.D., President and Chief Executive Officer,will present at the 20th Annual Piper Jaffray Health Care Conference in NewYork, NY, on Tuesday, December 2, 2008, at 10:10am (Eastern Standard Time).Dr. Mazzo will discuss the Company's development pipeline, in addition toreviewing recent business and clinical developments.
About Regado Biosciences
Regado Biosciences is pioneering a new therapeutic field with the creationand development of two-component drug systems, comprising an aptamertherapeutic that can be controlled directly by its specific and matchedreversal agent. Regado's technology is designed to give physicians theability to directly control and titrate each system's therapeutic effect.Enhanced control and flexibility allow physicians to meet the individual needsof patients independent of the setting. Regado is focusing its discovery anddevelopment efforts on acute care injectable antithrombotics, a multi-billiondollar market in need of therapeutics with improved safety profiles and agreater degree of therapeutic control.
Current investors in Regado include Domain (Princeton, NJ), QuakerBioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton AdvantageLife Sciences Fund (New York, NY), as well as individual investors, includingRobert Kierlin.
SOURCE Regado Biosciences